<p>At the first signs of an anaphylactic/anaphylactoid reaction, Pentoxifylline must be discontinued or the infusion be halted immediately, and a physician must be informed. Particularly careful monitoring is required:</p>

<ul>
	<li>in patients with severe cardiac arrhythmias</li>
	<li>in patients with myocardial infarction</li>
	<li>in hypotensive patients</li>
	<li>in patients with impaired renal function (creatinine clearance below 30 ml/min)</li>
	<li>in patients with severely impaired liver function</li>
	<li>in patients with increased bleeding</li>
	<li>in patients treated concomitantly with pentoxifylline and anti-vitamin K or platelet aggregation inhibitors</li>
	<li>in patients treated concomitantly with pentoxifylline and antidiabetic agents</li>
	<li>in patients treated concomitantly with pentoxifylline and ciprofoxacin</li>
	<li>in patients treated concomitantly with pentoxifylline and theophylline</li>
</ul>